All In Biotech

Drug Trial Radar · NCT03298945

Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens

Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,239 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,239

Actual

Start

Dec 13, 2018

Primary completion

Dec 30, 2023

Study completion Jun 30, 2024

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Oct 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

From the patients' perspective, the most formidable part of the colonoscopy experience is the process of bowel cleansing. A poorly tolerated bowel preparation regimen often leads to incompletion of scheduled colonoscopies which in turn undermines the effectiveness of colonoscopy, increases cost, and decreases patient satisfaction. The current standard bowel preparation in the VA is of larger volume and less palatable than another commonly used bowel preparation regimen. The investigators propose to compare these two commonly used bowel preparations with respect to the overall completion rate of scheduled colonoscopies in a real-world VA practice setting. The results of the study can be immediately applied to maximize the effectiveness of colonoscopy and increase patient satisfaction in the VA.

Conditions

  • Colorectal Cancer

Interventions

  • Miralax-Gatorade PrepDrug

    2-L split-dose Miralax-Gatorade bowel prep for colonoscopy

  • GolytelyDrug

    4-L split dose Golytely is the current standard prep at the VA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Colonoscopy Completion RateTime frame: This outcome is determined within 1 month after colonoscopy
  2. Population Level Adenoma Detection Rate (ADR)Time frame: within 1 month of colonoscopy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.